These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 19066192

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Relapsing demyelinating disease affecting both the central and peripheral nervous systems.
    Zéphir H, Stojkovic T, Latour P, Lacour A, de Seze J, Outteryck O, Maurage CA, Monpeurt C, Chatelet P, Ovelacq E, Vermersch P.
    J Neurol Neurosurg Psychiatry; 2008 Sep; 79(9):1032-9. PubMed ID: 18208860
    [Abstract] [Full Text] [Related]

  • 23. Factors predicting incomplete recovery from relapses in multiple sclerosis: a prospective study.
    Leone MA, Bonissoni S, Collimedaglia L, Tesser F, Calzoni S, Stecco A, Naldi P, Monaco F.
    Mult Scler; 2008 May; 14(4):485-93. PubMed ID: 18208889
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Spinal cord grey matter abnormalities are associated with secondary progression and physical disability in multiple sclerosis.
    Kearney H, Schneider T, Yiannakas MC, Altmann DR, Wheeler-Kingshott CA, Ciccarelli O, Miller DH.
    J Neurol Neurosurg Psychiatry; 2015 Jun; 86(6):608-14. PubMed ID: 25097217
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Cervical cord magnetization transfer ratio and clinical changes over 18 months in patients with relapsing-remitting multiple sclerosis: a preliminary study.
    Charil A, Caputo D, Cavarretta R, Sormani MP, Ferrante P, Filippi M.
    Mult Scler; 2006 Oct; 12(5):662-5. PubMed ID: 17086915
    [Abstract] [Full Text] [Related]

  • 29. Extent of cerebellum, subcortical and cortical atrophy in patients with MS: a case-control study.
    Ramasamy DP, Benedict RH, Cox JL, Fritz D, Abdelrahman N, Hussein S, Minagar A, Dwyer MG, Zivadinov R.
    J Neurol Sci; 2009 Jul 15; 282(1-2):47-54. PubMed ID: 19201003
    [Abstract] [Full Text] [Related]

  • 30. Early relapses, onset of progression, and late outcome in multiple sclerosis.
    Scalfari A, Neuhaus A, Daumer M, Deluca GC, Muraro PA, Ebers GC.
    JAMA Neurol; 2013 Feb 15; 70(2):214-22. PubMed ID: 23407713
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Association of multiple sclerosis susceptibility variants and early attack location in the CNS.
    Mowry EM, Carey RF, Blasco MR, Pelletier J, Duquette P, Villoslada P, Malikova I, Roger E, Kinkel RP, McDonald J, Bacchetti P, Waubant E.
    PLoS One; 2013 Feb 15; 8(10):e75565. PubMed ID: 24130718
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Histogram analysis of quantitative T1 and MT maps from ultrahigh field MRI in clinically isolated syndrome and relapsing-remitting multiple sclerosis.
    Al-Radaideh A, Mougin OE, Lim SY, Chou IJ, Constantinescu CS, Gowland P.
    NMR Biomed; 2015 Nov 15; 28(11):1374-82. PubMed ID: 26346925
    [Abstract] [Full Text] [Related]

  • 36. Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials.
    Bates D.
    Neurology; 2011 Jan 04; 76(1 Suppl 1):S14-25. PubMed ID: 21205678
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Contribution of cortical and white matter lesions to cognitive impairment in multiple sclerosis.
    Papadopoulou A, Müller-Lenke N, Naegelin Y, Kalt G, Bendfeldt K, Kuster P, Stoecklin M, Gass A, Sprenger T, Radue EW, Kappos L, Penner IK.
    Mult Scler; 2013 Sep 04; 19(10):1290-6. PubMed ID: 23459568
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study.
    Lublin FD, Bowen JD, Huddlestone J, Kremenchutzky M, Carpenter A, Corboy JR, Freedman MS, Krupp L, Paulo C, Hariri RJ, Fischkoff SA.
    Mult Scler Relat Disord; 2014 Nov 04; 3(6):696-704. PubMed ID: 25891548
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.